

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06	Engineering Information Encompass files have new names
NEWS	4	Feb 16	TOXLINE no longer being updated
NEWS	5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07	DGENE Reload
NEWS	8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS	9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS	10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS	11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS	12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS	13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	17	Oct 22	Over 1 million reactions added to CASREACT
NEWS	18	Oct 22	DGENE GETSIM has been improved
NEWS	19	Oct 29	AAASD no longer available
NEWS	20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	22	Nov 29	COPPERLIT now available on STN
NEWS	23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	24	Nov 30	Files VETU and VETB to have open access
NEWS	25	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	26	Dec 10	DGENE BLAST Homology Search
NEWS	27	Dec 17	WELDASEARCH now available on STN
NEWS	28	Dec 17	STANDARDS now available on STN
NEWS	29	Dec 17	New fields for DPCI
NEWS	30	Dec 19	CAS Roles modified
NEWS	31	Dec 19	1907-1946 data and page images added to CA and Caplus
NEWS EXPRESS			August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:39:10 ON 28 DEC 2001

=> file medline, biosis, uspatful, dgene, japio, embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 18:39:35 ON 28 DEC 2001

FILE 'BIOSIS' ENTERED AT 18:39:35 ON 28 DEC 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 18:39:35 ON 28 DEC 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:39:35 ON 28 DEC 2001  
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 18:39:35 ON 28 DEC 2001  
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'EMBASE' ENTERED AT 18:39:35 ON 28 DEC 2001  
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

=> s codon replacment

L1 0 CODON REPLACEMENT

=> s codon

L2 107597 CODON

=> s l2 and replacement

L3 7806 L2 AND REPLACEMENT

=> s l3 and encoding protein

L4 101 L3 AND ENCODING PROTEIN

=> s l4 and frequency

L5 40 L4 AND FREQUENCY

=> s l5 and less common

L6 0 L5 AND LESS COMMON

=> d l5 ti abs ibib 1-10

L5 ANSWER 1 OF 40 USPTFULL  
 TI Evolution of whole cells and organisms by recursive sequence recombination  
 AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:220889 USPTFULL  
 TITLE: Evolution of whole cells and organisms by recursive sequence recombination  
 INVENTOR(S): delCardayre, Stephen, Los Gatos, CA, United States  
 Tobin, Matthew, San Jose, CA, United States  
 Stemmer, William P. C., Los Gatos, CA, United States  
 Ness, Jon E., Sunnyvale, CA, United States  
 Minshull, Jeremy, Menlo Park, CA, United States  
 Patten, Phillip, Mountain View, CA, United States  
 Subramanian, Venkiteswatan, Danville, CA, United States  
 States Castle, Linda, Mountain View, CA, United States  
 Bass, Steve, Hillsborough, CA, United States  
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326204	B1	20011204
APPLICATION INFO.:	US 1998-116188		19980715 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US852, filed on 16 Jan 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Whisenant, Ethan		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan Law Offices of Jonathan Alan Quine		
NUMBER OF CLAIMS:	49		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	5175		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 40 USPTFULL  
 TI Methods and compositions for polypeptide engineering  
 AB Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:208690 USPTFULL  
 TITLE: Methods and compositions for polypeptide engineering  
 INVENTOR(S): Patten, Phillip A., Mountain View, CA, United States  
 Stemmer, Willem P. C., Los Gatos, CA, United States  
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6319713	B1	20011120
APPLICATION INFO.:	US 1999-339904		19990625 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-769062, filed on 18 Dec 1996 Continuation-in-part of Ser. No. US 1994-198431, filed on 17 Feb 1994, now patented, Pat. No. US

5605793

, said Ser. No. US 769062 And Ser. No. US 339904 Continuation-in-part of Ser. No. US 537874, now patented, Pat. No. US 5830721 , said Ser. No. US

339904

And Ser. No. US 339904 And Ser. No. WO 1996-US5480, filed on 18 Dec 1996 Continuation-in-part of Ser. No. US 1996-722660, filed on 27 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-675502, filed on 3 Jul 1996, now patented, Pat. No. US 5928905 Continuation-in-part of Ser. No. US 1996-721824, filed on 20 May 1996 Continuation-in-part of Ser. No. US 1996-650400, filed on 20 May 1996, now patented, Pat. No. US 5837458 Continuation-in-part of Ser. No. US 1996-621430, filed on 25 Mar 1996, now abandoned Continuation-in-part of Ser. No. US 1996-621859, filed on 25 Mar 1996, now patented, Pat. No. US 6117679 Continuation-in-part of Ser. No. US 1995-425684, filed on 18 Apr 1995, now patented, Pat. No. US 5834252 Continuation-in-part of Ser. No. US 1995-425684, filed on 18 Apr 1995, now patented, Pat. No. US 5834252

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Whisenant, Ethan  
LEGAL REPRESENTATIVE: Kruse, Norman J., Quire, Jonathan AlanThe Law Office at

Jonathan Alan Quire

NUMBER OF CLAIMS: 53  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 4356  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 40 USPATFULL

TI Methods and compositions for polypeptide engineering  
AB Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:178848 USPATFULL  
TITLE: Methods and compositions for polypeptide engineering  
INVENTOR(S): Patten, Phillip A., Mountain View, CA, United States  
Stemmer, Willem P.C., Los Gatos, CA, United States  
PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303344	B1	20011016
APPLICATION INFO.:	US 1999-339913		19990624 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-769062, filed on 18 Dec 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Whisenant, Ethan		
ASSISTANT EXAMINER:	Tung, Joyce		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan AlanThe Law Office of		
	Jonathan Alan Quine		

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 3923  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 40 USPATFULL

TI MDKI, a novel receptor tyrosine kinase

AB The present invention relates to MDK1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing.

Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a MDK1 receptor tyrosine kinase and a receptor for the kinase. The MDK1 receptor tyrosine kinase may be truncated and lack a kinase domain and may be selected from the group consisting of MDK1.T1, MDK1.T2, MDK1..DELTA.1 and MDK1..DELTA.2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:173726 USPATFULL  
TITLE: MDKI, a novel receptor tyrosine kinase  
INVENTOR(S): Ciossek, Thomas, Munich, Germany, Federal Republic of Ullrich, Axel, Portola Valley, CA, United States Millauer, Birgit, Belmont, CA, United States  
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft Zuer Forderung Der, Munich, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300482	B1	20011009
APPLICATION INFO.:	US 1995-368776		19950103 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ungar, Susan		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	3535		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 40 USPATFULL

TI Method of increasing production of disulfide bonded recombinant proteins

by saccharomyces cerevisiae  
AB Disclosed is a process for increasing the yield of disulfide bonded recombinant proteins produced by yeast, especially recombinant secreted proteins. The enzyme protein disulfide isomerase (PDI) catalyzes the formation of disulfide bonds in secretory and cell-surface proteins. We disclose the construction of recombinant strains of the yeast Saccharomyces cerevisiae which overproduce either human PDI or yeast

PDI  
in a regulated fashion. These strains show greatly increased secretion of disulfide bonded proteins of potential therapeutic significance. These strains have the potential to increase the production of various disulfide bonded proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:158037 USPATFULL  
TITLE: Method of increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae

INVENTOR(S): Tuite, Michael F., Chartham Hatch, United Kingdom  
 Freedman, Robert B., Canterbury, United Kingdom  
 Shultz, Loren D., Harleysville, United States  
 Ellis, Ronald W., Newton, MA, United States  
 Markus, Henry Z., Wyncote, PA, United States  
 Montgomery, Donna L., Chalfont, PA, United States  
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 University of Kent at Canterbury, Kent, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291205	B1	20010918
APPLICATION INFO.:	US 1992-901713		19920612 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Hand, J. Mark, Tribble, Jack L.		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1927		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 40 USPATFULL  
 TI Evolution of whole cells and organisms by recursive sequence recombination  
 AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2001:152770 USPATFULL  
 TITLE: Evolution of whole cells and organisms by recursive sequence recombination  
 INVENTOR(S): delCardayre, Stephen, Belmont, CA, United States  
 Tobin, Matthew, San Jose, CA, United States  
 Stemmer, Willem P. C., Los Gatos, CA, United States  
 Ness, Jon E., Sunnyvale, CA, United States  
 Minshull, Jeremy, Menlo Park, CA, United States  
 Patten, Phillip, Menlo Park, CA, United States  
 Subramanian, Venkiteswaran, San Diego, CA, United States  
 Castle, Linda, Mountain View, CA, United States  
 Krebber, Claus M., Mountain View, CA, United States  
 Bass, Steven H., Hillsborough, CA, United States  
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287862	B1	20010911
APPLICATION INFO.:	US 2000-626410		20000726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-116188, filed on 15 Jul 1998 Continuation-in-part of Ser. No. WO 1998-US852, filed on 16 Jan 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054	19970107 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Whisenant, Ethan  
 LEGAL REPRESENTATIVE: Kruse, Norman J., Quine, Jonathan Alan The Law Offices  
 of Jonathan Alan Quine  
 NUMBER OF CLAIMS: 48  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 35 Drawing Figure(s); 35 Drawing Page(s)  
 LINE COUNT: 5146  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 40 USPATFULL  
 TI Glaucoma compositions  
 AB Glaucoma compositions comprising the GLC1A gene are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2001:125799 USPATFULL  
 TITLE: Glaucoma compositions  
 INVENTOR(S): Stone, Edwin M., Iowa City, IA, United States  
 Sheffield, Val C., Coralville, IA, United States  
 Alward, Wallace L. M., Iowa City, IA, United States  
 PATENT ASSIGNEE(S): The University of Iowa Research Foundation, Iowa City,  
 IA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271026	B1	20010807
APPLICATION INFO.:	US 1997-822999		19970321 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Martin, Jill D.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot LLP, Arnold, Beth E., Varma, Anita		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	3481		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 40 USPATFULL  
 TI Evolution of whole cells and organisms by recursive sequence  
 recombination  
 AB The invention provides methods employing iterative cycles of  
 recombination and selection/screening for evolution of whole cells and  
 organisms toward acquisition of desired properties. Examples of such  
 properties include enhanced recombinogenicity, genome copy number, and  
 capacity for expression and/or secretion of proteins and secondary  
 metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2001:97699 USPATFULL  
 TITLE: Evolution of whole cells and organisms by recursive  
 sequence recombination  
 INVENTOR(S): Tobin, Matthew, San Jose, CA, United States  
 Stemmer, William P. C., Los Gatos, CA, United States  
 Ness, Jon E., Sunnyvale, CA, United States  
 Minshull, Jeremy, Menlo Park, CA, United States  
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251674	B1	20010626
APPLICATION INFO.:	US 2000-499505		20000207 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 116188		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054	19970107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Whisenant, Ethan	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan	The Law Offices of Jonathan Alan Quine
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)	
LINE COUNT:	5013	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 9 OF 40 USPATFULL

TI Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases  
 AB Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:93642 USPATFULL  
 TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases  
 INVENTOR(S): Barry, Gerard Francis, St. Louis, MO, United States  
 Kishore, Ganesh Murthy, Chesterfield, MO, United States  
 Padgette, Stephen Rogers, Grover, MO, United States  
 Stallings, William Carlton, Glencoe, MO, United States  
 PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248876	B1	20010619
APPLICATION INFO.:	US 1998-137440		19980820 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-833485, filed on 7 Apr 1997, now patented, Pat. No. US 5804425 Continuation of Ser. No. US 1994-306063, filed on 13 Sep 1994, now patented, Pat. No. US 5633435 Continuation-in-part of Ser. No. US 1991-749611, filed on 28 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1990-576537, filed on 31 Aug 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Slobodyansky, Elizabeth		
LEGAL REPRESENTATIVE:	Bonner, Esq., Grace L., Simon, Howrey	Arnold & White LLP	
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	70 Drawing Figure(s); 70 Drawing Page(s)		
LINE COUNT:	3117		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L5 ANSWER 10 OF 40 USPATFULL  
TI Nucleic acids that control endosperm development in plants  
AB The invention provides methods of controlling endosperm development in plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:67875 USPATFULL  
TITLE: Nucleic acids that control endosperm development in plants  
INVENTOR(S): Fischer, Robert L., El Cerrito, CA, United States  
Ohad, Nir, Jerusalem, Israel  
Kiyosue, Tomohiro, Okazaki, Japan  
Yadegari, Ramin, San Jose, CA, United States  
Margossian, Linda, El Cerrito, CA, United States  
Harada, John, Davis, CA, United States  
Goldberg, Robert B., Topanga, CA, United States  
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6229064	B1	20010508
APPLICATION INFO.:	US 1998-177249		19981022 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-71838, filed on 1 May 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula		
ASSISTANT EXAMINER:	Mehta, Ashwin D.		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1,12		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1399		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:39:10 ON 28 DEC 2001)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, JAPIO, EMBASE' ENTERED AT 18:39:35 ON 28 DEC 2001

L1 0 S CODON REPLACEMENT  
L2 107597 S CODON  
L3 7806 S L2 AND REPLACEMENT  
L4 101 S L3 AND ENCODING PROTEIN  
L5 40 S L4 AND FREQUENCY  
L6 0 S L5 AND LESS COMMON

=> d l5 ti abs ibib 30-40

L5 ANSWER 30 OF 40 USPATFULL  
TI Polynucleotides encoding improved humanized immunoglobulins  
AB Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are

immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:112587 USPATFULL  
TITLE: Polynucleotides encoding improved humanized immunoglobulins  
INVENTOR(S): Queen, Cary L., Los Altos, CA, United States  
Schneider, William P., Mountain View, CA, United States  
PATENT ASSIGNEE(S): Selick, Harold E., Belmont, CA, United States  
Protein Design Labs, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693761		19971202
APPLICATION INFO.:	US 1995-474040		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-634278, filed on 19 Dec 1990, now patented, Pat. No. US 5530101, issued on 25 Jun 1996 which is a continuation of Ser. No. US 1990-590274, filed on 28 Sep 1990, now abandoned And a continuation of Ser. No. US 1989-310252, filed on 13 Feb 1989, now abandoned which is a continuation of Ser. No. US 1988-290975, filed on 28 Dec 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Reeves, Julie E.		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	80 Drawing Figure(s); 55 Drawing Page(s)		
LINE COUNT:	4810		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 40 USPATFULL

TI Fusion proteins comprising circularly permuted ligands  
AB The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original (unpermuted) ligand. The invention further provides for novel fusion proteins comprising a circularly permuted ligand fused to one or more proteins of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:47503 USPATFULL  
TITLE: Fusion proteins comprising circularly permuted ligands  
INVENTOR(S): Pastan, Ira H., Potomac, MD, United States  
Kreitman, Robert J., Potomac, MD, United States  
Puri, Raj K., North Potomac, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington,

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5635599		19970603
APPLICATION INFO.:	US 1994-225224		19940408 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Walsh, Stephen G.		
ASSISTANT EXAMINER:	Kemmerer, Elizabeth C.		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1966		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 40 USPATFULL

TI Method of detecting ligand interactions

AB Provided by the present invention are novel methods of detecting ligand interactions, as well as reagents useful in the method, including DNA and

host cells; and more specifically relates to novel methods for the detection of protein/protein interactions and their application in epitope mapping and the study of ligand/receptor interactions. Also provided are vaccines and kits comprising the expression products and host cells of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:47098 USPATFULL

TITLE: Method of detecting ligand interactions

INVENTOR(S): McCoy, John M., Reading, MA, United States

Lu, Zhijian, Arlington, MA, United States

PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5635182		19970603
APPLICATION INFO.:	US 1994-260582		19940616 (8)
DISCLAIMER DATE:	20101214		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Bugalsky, Gabriele E.		
LEGAL REPRESENTATIVE:	Meinert, M. C.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1935		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 40 USPATFULL

TI Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases

AB Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with

known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:45193 USPATFULL

TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases

INVENTOR(S): Barry, Gerard F., St. Louis, MO, United States  
Kishore, Ganesh M., Chesterfield, MO, United States  
Padgette, Stephen R., Grover, MO, United States  
Stallings, William C., Glencoe, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633435		19970527
APPLICATION INFO.:	US 1994-306063		19940913 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-749611, filed on 28 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-576537, filed on 31 Aug 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chereskin, Che S.		
LEGAL REPRESENTATIVE:	Hoerner, Jr., Dennis R.		
NUMBER OF CLAIMS:	87		
EXEMPLARY CLAIM:	4		
NUMBER OF DRAWINGS:	70 Drawing Figure(s); 70 Drawing Page(s)		
LINE COUNT:	3863		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 40 USPATFULL

TI Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases

AB Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology

with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:38404 USPATFULL

TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases

INVENTOR(S): Barry, Gerard F., St. Louis, MO, United States  
Kishore, Ganesh M., Chesterfield, MO, United States  
Padgette, Stephen R., Grover, MO, United States  
Stallings, William C., Glencoe, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627061		19970506
APPLICATION INFO.:	US 1995-476008		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-306063, filed on 13 Sep 1994 which is a continuation-in-part of Ser. No. US 1991-749611, filed on 28 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-576537, filed on 31 Aug 1990, now abandoned		

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Chereskin, Che S.  
 LEGAL REPRESENTATIVE: Hoerner, Jr., Dennis R.  
 NUMBER OF CLAIMS: 8  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 70 Drawing Figure(s); 70 Drawing Page(s)  
 LINE COUNT: 3576  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 40 USPATFULL

TI Virulence-encoding DNA sequences of Streptococcus suis and related products and methods

AB The invention provides DNA sequences which code for polypeptides which are characteristic for the virulence of the pathogenic bacterium Streptococcus suis and parts thereof, and polypeptides and antibodies derived therefrom. The sequences code for a polypeptide of 90,000-120,000 daltons or a polypeptide of higher molecular weight containing such a polypeptide, and for a polypeptide of 135,000-136,000 daltons (muramidase released protein), or parts thereof. The sequences themselves, and also the polypeptides and antibodies derived therefrom, are used for diagnosis of and protection against infection by S. suis

in mammals, including man.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:20384 USPATFULL  
 TITLE: Virulence-encoding DNA sequences of Streptococcus suis and related products and methods  
 INVENTOR(S): Smith, Hilda E., Cz Lelystad, Netherlands  
 Vecht, Uri, As Ermelo, Netherlands  
 PATENT ASSIGNEE(S): Centraal Diergeneeskundig Instituut, PH Lelystad, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5610011		19970311
	WO 9216630		19920110
APPLICATION INFO.:	US 1993-119125		19930920 (8)
	WO 1992-NL54		19920319
			19930920 PCT 371 date
			19930920 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	NL 1991-510	19910321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Campell, Bruce R.	
LEGAL REPRESENTATIVE:	Handal & Morofsky	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	2515	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 36 OF 40 USPATFULL

TI Humanized immunoglobulins

AB Novel methods for producing, and compositions of humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin

framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:116100 USPATFULL  
 TITLE: Humanized immunoglobulins  
 INVENTOR(S): Queen, Cary L., Los Altos, CA, United States  
 Selick, Harold E., Belmont, CA, United States  
 PATENT ASSIGNEE(S): Protein Design Labs, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5585089		19961217
APPLICATION INFO.:	US 1995-477728		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-634278, filed on 19 Dec 1990, now patented, Pat. No. US 5530101 which is a continuation-in-part of Ser. No. US 1990-590274, filed on 28 Sep 1990, now abandoned And Ser. No. US 1989-310252, filed on 13 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-290975, filed on 28 Dec 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	4		
NUMBER OF DRAWINGS:	80 Drawing Figure(s); 55 Drawing Page(s)		
LINE COUNT:	4605		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 40 USPATFULL

TI Humanized immunoglobulins

AB Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:55856 USPATFULL  
 TITLE: Humanized immunoglobulins  
 INVENTOR(S): Queen, Cary L., Los Altos, CA, United States  
 Selick, Harold E., Belmont, CA, United States

PATENT ASSIGNEE(S): Protein Design Labs, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5530101		19960625
APPLICATION INFO.:	US 1990-634278		19901219 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-590274, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1989-310252, filed on 13 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-290975, filed on 28 Dec 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	80 Drawing Figure(s); 55 Drawing Page(s)		
LINE COUNT:	4526		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 40 USPATFULL

TI Process for the site-directed integration of DNA into the genome of plants

AB The present invention provides a method for site-directed integration of

of DNA-sequences into the genome of plants via homologous recombination, by

transforming said plants using the DNA-transfer system of

Agrobacterium, in which the transforming DNA comprises in its most simple form a region

homologous to the target locus, as well as a region which is different from the target locus either next to one or between two T-DNA borders. Special constructs are provided, which in its most complete form have the following general structure, ##STR1## in which box 1 and 7 represent

T-DNA borders, boxes 2 and 6 comprise functional expression cassettes containing negative selection genes, box 3 provides a region of

homology with the target locus promoting recombination, box 4 represents a DNA sequence containing a mutation with respect to the target locus, box 5 represents a functional expression cassette containing a positive selection gene, and box E comprises a DNA sequence which is homologous to a region adjacent of the target locus, or in the vicinity of the target locus, which promotes homologous recombination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:24854 USPATFULL

TITLE: Process for the site-directed integration of DNA into the genome of plants

INVENTOR(S): Offringa, Remko, Leiden, Netherlands  
De Groot, Marcellus J. A., Utrecht, Netherlands  
Hooykaas, Paul J. J., Oegstgeest, Netherlands  
Van Den Elzen, Petrus J. M., Voorhout, Netherlands

PATENT ASSIGNEE(S): Mogen International, n.v./Rijksuniversiteit te Leiden, Leiden, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5501967		19960326
APPLICATION INFO.:	US 1993-87928		19930706 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	NL 1989-1931	19890726
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fox, David T.	
LEGAL REPRESENTATIVE:	Morrison & Foerster	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	1812	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 40 USPATFULL

TI DNA encoding 85kd polypeptide useful in diagnosis of Mycoplasma  
infections in animals

AB A class of polypeptides useful in an in vitro diagnosis of Mycoplasma  
infection in animals is disclosed. These polypeptides are also capable  
of inducing an immune response in swine which were previously not  
exposed to Mycoplasma. Recombinant DNA methods for the production of  
these polypeptides and certain phage vectors and DNA sequences useful  
in  
these methods are also disclosed. Methods of vaccinating animals  
utilizing a vaccination composition which includes these polypeptides  
is  
also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 95:92697 USPATFULL

TITLE: DNA encoding 85kd polypeptide useful in diagnosis of  
Mycoplasma infections in animals

INVENTOR(S): Kuner, Jerry, Longmont, CO, United States  
Ko, Christine, Boulder, CO, United States

PATENT ASSIGNEE(S): Synergen, Inc., Boulder, CO, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5459048		19951017